Tonix licenses SARS-CoV-2 antiviral inhibitor from OyaGen

By The Science Advisory Board staff writers

April 19, 2021 -- Tonix Pharmaceuticals has agreed to obtain the exclusive worldwide license for TNX-3500 (previously OYA1), an antiviral inhibitor of SARS-CoV-2 developed by OyaGen, for the treatment of COVID-19 and potentially other viral disorders.

The active ingredient of TNX-3500 is a nucleoside analog that inhibits protein kinase C. It has been studied in humans in prior clinical studies of cancer patients at the U.S. National Cancer Institute, but has not been approved for marketing, according to the firm. The candidate is in the preinvestigational new drug (IND) phase of development and has demonstrated success in cell culture inhibition studies with SARS-CoV-2.

Under the agreement, Tonix has been granted an exclusive license from OyaGen for the technology and patents related to TNX-3500 and other related compounds. Tonix will conduct further studies to test the safety and efficacy of TNX-3500 in treating COVID-19 as necessary to reach regulatory approval. Financial terms were not disclosed.

Tonix files patent for proprietary monoclonal antibody
Tonix Pharmaceuticals has filed a patent application for TNX-1500, a humanized monoclonal antibody directed against the CD40-ligand, with the World Intellectual...
Tonix touts positive preclinical COVID-19 vaccine results
Tonix Pharmaceuticals has released preliminary results from nonhuman primate studies with TNX-1800, a live-attenuated COVID-19 vaccine candidate engineered...
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter